Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 25

Related Articles by Review for PubMed (Select 23131380)

1.

The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders.

Yang CW, Mousa SA.

Complement Ther Med. 2012 Dec;20(6):466-74. doi: 10.1016/j.ctim.2012.07.004. Epub 2012 Aug 17. Review.

PMID:
23131380
2.

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Tenenbaum A, Fisman EZ, Motro M, Adler Y.

Adv Cardiol. 2008;45:127-53. doi: 10.1159/0000115192. Review.

PMID:
18230960
3.

Red yeast rice for dysipidemia.

Shamim S, Al Badarin FJ, DiNicolantonio JJ, Lavie CJ, O'Keefe JH.

Mo Med. 2013 Jul-Aug;110(4):349-54. Review.

PMID:
24003656
4.

Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions.

Feng Y, Xu H, Chen K.

J Altern Complement Med. 2012 Apr;18(4):318-28. doi: 10.1089/acm.2011.0187. Epub 2012 Apr 10. Review.

PMID:
22489805
5.

Review of red yeast rice content and current Food and Drug Administration oversight.

Childress L, Gay A, Zargar A, Ito MK.

J Clin Lipidol. 2013 Mar-Apr;7(2):117-22. doi: 10.1016/j.jacl.2012.09.003. Epub 2012 Sep 25. Review.

PMID:
23415430
6.

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125. Review.

7.
8.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
9.
11.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

PMID:
16849903
12.
13.
14.

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

Yee HS, Fong NT.

Ann Pharmacother. 1998 Oct;32(10):1030-43. Review.

PMID:
9793596
15.
16.

Management of dyslipidemia in the primary prevention of coronary heart disease.

Singh BK, Mehta JL.

Curr Opin Cardiol. 2002 Sep;17(5):503-11. Review.

PMID:
12357127
17.

[Ezetimibe: from pharmacology to clinical trials].

Tellier P.

Ann Endocrinol (Paris). 2003 Dec;64(6):442-7. Review. French.

PMID:
15067249
18.

[Statins in primary prevention of coronary heart disease].

Paulweber B.

Wien Med Wochenschr. 1999;149(5-6):129-38. Review. German.

PMID:
10408004
19.

[A new approach to the treatment of dyslipidemia].

Kevelaitiene S, Slapikas R.

Medicina (Kaunas). 2008;44(5):407-13. Review. Lithuanian.

20.

The treatment of dyslipidemia--what's left in the pipeline?

Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.

ChemMedChem. 2008 Feb;3(2):206-21. Review.

PMID:
17963209
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk